These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 15908662)

  • 1. Clinical value of mitochondrial mutations in colorectal cancer.
    Lièvre A; Chapusot C; Bouvier AM; Zinzindohoué F; Piard F; Roignot P; Arnould L; Beaune P; Faivre J; Laurent-Puig P
    J Clin Oncol; 2005 May; 23(15):3517-25. PubMed ID: 15908662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
    Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
    Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
    van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
    J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid.
    Zhu W; Qin W; Bradley P; Wessel A; Puckett CL; Sauter ER
    Carcinogenesis; 2005 Jan; 26(1):145-52. PubMed ID: 15375011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High rate of mutation in mitochondrial DNA displacement loop region in human colorectal cancer.
    Akouchekian M; Houshmand M; Hemati S; Ansaripour M; Shafa M
    Dis Colon Rectum; 2009 Mar; 52(3):526-30. PubMed ID: 19333057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy.
    Aschele C; Debernardis D; Lonardi S; Bandelloni R; Casazza S; Monfardini S; Gallo L
    J Clin Oncol; 2004 Sep; 22(18):3758-65. PubMed ID: 15365072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma.
    Lièvre A; Blons H; Houllier AM; Laccourreye O; Brasnu D; Beaune P; Laurent-Puig P
    Br J Cancer; 2006 Mar; 94(5):692-7. PubMed ID: 16495928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin.
    Ichikawa W; Ooyama A; Toda E; Sugimoto Y; Oka T; Takahashi T; Shimizu M; Sasaki Y; Hirayama R
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):794-801. PubMed ID: 16528528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
    Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
    J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
    Chen SP; Wu CC; Lin SZ; Kang JC; Su CC; Chen YL; Lin PC; Chiu SC; Pang CY; Harn HJ
    Am J Clin Oncol; 2009 Apr; 32(2):122-6. PubMed ID: 19307944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.
    Gnanasampanthan G; Elsaleh H; McCaul K; Iacopetta B
    J Pathol; 2001 Dec; 195(5):543-8. PubMed ID: 11745689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers.
    Krajewska M; Kim H; Kim C; Kang H; Welsh K; Matsuzawa S; Tsukamoto M; Thomas RG; Assa-Munt N; Piao Z; Suzuki K; Perucho M; Krajewski S; Reed JC
    Clin Cancer Res; 2005 Aug; 11(15):5451-61. PubMed ID: 16061861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer.
    Tseng LM; Yin PH; Chi CW; Hsu CY; Wu CW; Lee LM; Wei YH; Lee HC
    Genes Chromosomes Cancer; 2006 Jul; 45(7):629-38. PubMed ID: 16568452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Number of somatic mutations in the mitochondrial D-loop region indicates poor prognosis in breast cancer, independent of TP53 mutation.
    Kuo SJ; Chen M; Ma GC; Chen ST; Chang SP; Lin WY; Chen YC; Lee TH; Lin TT; Liu CS
    Cancer Genet Cytogenet; 2010 Sep; 201(2):94-101. PubMed ID: 20682393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of adjuvant chemotherapy on patients with stage III colorectal cancer: l-LV/5FU chemotherapy as a modified RPMI regimen is an independent prognostic factor for survival.
    Hotta T; Takifuji K; Arii K; Yokoyama S; Matsuda K; Higashiguchi T; Tominaga T; Oku Y; Yamaue H
    Anticancer Res; 2006; 26(2B):1425-32. PubMed ID: 16619554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance.
    Jantscheff P; Terracciano L; Lowy A; Glatz-Krieger K; Grunert F; Micheel B; Brümmer J; Laffer U; Metzger U; Herrmann R; Rochlitz C
    J Clin Oncol; 2003 Oct; 21(19):3638-46. PubMed ID: 14512395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
    Tang R; Wang JY; Fan CW; Tsao KC; Chen HH; Wu CM; Chen JS; Changchien CR; Hsieh LL
    Cancer Lett; 2004 Jul; 210(1):101-9. PubMed ID: 15172127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
    Storojeva I; Boulay JL; Heinimann K; Ballabeni P; Terracciano L; Laffer U; Mild G; Herrmann R; Rochlitz C
    Oncol Rep; 2005 Jul; 14(1):241-9. PubMed ID: 15944796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.